|
1
|
Slaughter DP, Southwick HW and Smejkal W:
Field cancerization in oral stratified squamous epithelium;
clinical implications of multicentric origin. Cancer. 6:963–968.
1953. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Angadi PV, Savitha JK, Rao SS and
Sivaranjini Y: Oral field cancerization: Current evidence and
future perspectives. Oral Maxillofac Surg. 16:171–180. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Braakhuis BJ, Tabor MP, Kummer JA, Leemans
CR and Brakenhoff RH: A genetic explanation of Slaughter's concept
of field cancerization: Evidence and clinical implications. Cancer
Res. 63:1727–1730. 2003.PubMed/NCBI
|
|
4
|
Curtius K, Wright NA and Graham TA: An
evolutionary perspective on field cancerization. Nat Rev Cancer.
18:19–32. 2018. View Article : Google Scholar
|
|
5
|
Takeshima H and Ushijima T: Accumulation
of genetic and epigenetic alterations in normal cells and cancer
risk. NPJ Precis Oncol. 3:72019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lochhead P, Chan AT, Nishihara R, Fuchs
CS, Beck AH, Giovannucci E and Ogino S: Etiologic field effect:
Reappraisal of the field effect concept in cancer predisposition
and progression. Mod Pathol. 28:14–29. 2015. View Article : Google Scholar
|
|
7
|
Gabriel KN, Jones AC, Nguyen JP, Antillon
KS, Janos SN, Overton HN, Jenkins SM, Frisch EH, Trujillo KA and
Bisoffi M: Association and regulation of protein factors of field
effect in prostate tissues. Int J Oncol. 49:1541–1552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haaland CM, Heaphy CM, Butler KS, Fischer
EG, Griffith JK and Bisoffi M: Differential gene expression in
tumor adjacent histologically normal prostatic tissue indicates
field cancerization. Int J Oncol. 35:537–546. 2009.PubMed/NCBI
|
|
9
|
Heaphy CM, Fleet TM, Treat EG, Lee SJ,
Smith AY, Davis MS, Griffith JK, Fischer EG and Bisoffi M:
Organ-wide telomeric status in diseased and disease-free prostatic
tissues. Prostate. 70:1471–1479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones AC, Antillon KS, Jenkins SM, Janos
SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA and Bisoffi M:
Prostate field cancerization: Deregulated expression of macrophage
inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A
(PDGF-A) in tumor adjacent tissue. PLoS One. 10:e01193142015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones AC, Trujillo KA, Phillips GK, Fleet
TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK,
et al: Early growth response 1 and fatty acid synthase expression
is altered in tumor adjacent prostate tissue and indicates field
cancerization. Prostate. 72:1159–1170. 2012. View Article : Google Scholar
|
|
12
|
Treat EG, Heaphy CM, Massie LW, Bisoffi M,
Smith AY, Davis MS and Griffith JK: Telomere DNA content in
prostate biopsies predicts early rise in prostate-specific antigen
after radical prostatectomy for prostate cancer. Urology.
75:724–729. 2010. View Article : Google Scholar
|
|
13
|
Trujillo KA, Jones AC, Griffith JK and
Bisoffi M: Markers of field cancerization: Proposed clinical
applications in prostate biopsies. Prostate Cancer.
2012:3028942012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nonn L, Ananthanarayanan V and Gann PH:
Evidence for field cancerization of the prostate. Prostate.
69:1470–1479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi JY, Kim S, Kwak HB, Park DH, Park JH,
Ryu JS, Park CS and Kang JH: Extracellular Vesicles as a Source of
Urological Biomarkers: Lessons Learned From Advances and Challenges
in Clinical Applications to Major Diseases. Int Neurourol J.
21:83–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dhondt B, Van Deun J, Vermaerke S, de
Marco A, Lumen N, De Wever O and Hendrix A: Urinary extracellular
vesicle biomarkers in urological cancers: From discovery towards
clinical implementation. Int J Biochem Cell Biol. 99:236–256. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan J, Ding M, Xu K, Yang C and Mao LJ:
Exosomes in diagnosis and therapy of prostate cancer. Oncotarget.
8:97693–97700. 2017.PubMed/NCBI
|
|
18
|
Vlaeminck-Guillem V: Extracellular
Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and
Management. Front Oncol. 8:2222018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Panigrahi GK and Deep G: Exosomes-based
biomarker discovery for diagnosis and prognosis of prostate cancer.
Front Biosci. 22:1682–1696. 2017. View
Article : Google Scholar
|
|
20
|
Soekmadji C, Russell PJ and Nelson CC:
Exosomes in prostate cancer: Putting together the pieces of a
puzzle. Cancers (Basel). 5:1522–1544. 2013. View Article : Google Scholar
|
|
21
|
Fordyce CA, Heaphy CM, Joste NE, Smith AY,
Hunt WC and Griffith JK: Association between cancer-free survival
and telomere DNA content in prostate tumors. J Urol. 173:610–614.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Mora GR, Olivier KR, Cheville JC, Mitchell
RF Jr, Lingle WL and Tindall DJ: The cytoskeleton differentially
localizes the early growth response gene-1 protein in cancer and
benign cells of the prostate. Mol Cancer Res. 2:115–128.
2004.PubMed/NCBI
|
|
24
|
Duijvesz D, Burnum-Johnson KE, Gritsenko
MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider
T, Paša-Tolić L and Jenster G: Proteomic profiling of exosomes
leads to the identification of novel biomarkers for prostate
cancer. PLoS One. 8:e825892013. View Article : Google Scholar
|
|
25
|
Malla RR, Pandrangi S, Kumari S, Gavara MM
and Badana AK: Exosomal tetraspanins as regulators of cancer
progression and metastasis and novel diagnostic markers. Asia Pac J
Clin Oncol. 14:383–391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizutani K, Terazawa R, Kameyama K, Kato
T, Horie K, Tsuchiya T, Seike K, Ehara H, Fujita Y, Kawakami K, et
al: Isolation of prostate cancer-related exosomes. Anticancer Res.
34:3419–3423. 2014.PubMed/NCBI
|
|
27
|
Dakubo GD, Jakupciak JP, Birch-Machin MA
and Parr RL: Clinical implications and utility of field
cancerization. Cancer Cell Int. 7:22007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bjurlin MA, Meng X, Le Nobin J, Wysock JS,
Lepor H, Rosenkrantz AB and Taneja SS: Optimization of prostate
biopsy: The role of magnetic resonance imaging targeted biopsy in
detection, localization and risk assessment. J Urol. 192:648–658.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bostanci Y, Kazzazi A and Djavan B:
Optimizing prostate biopsy. Minerva Urol Nefrol. 64:233–243.
2012.
|
|
30
|
Delongchamps NB and Haas GP: Saturation
biopsies for prostate cancer: Current uses and future prospects.
Nat Rev Urol. 6:645–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rabbani F, Stroumbakis N, Kava BR, Cookson
MS and Fair WR: Incidence and clinical significance of
false-negative sextant prostate biopsies. J Urol. 159:1247–1250.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Halin S, Hammarsten P, Adamo H, Wikström P
and Bergh A: Tumor indicating normal tissue could be a new source
of diagnostic and prognostic markers for prostate cancer. Expert
Opin Med Diagn. 5:37–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mazzucchelli R, Galosi AB, Santoni M,
Lopez-Beltran A, Scarpelli M, Cheng L and Montironi R: Role of the
pathologist in active surveillance for prostate cancer. Anal Quant
Cytopathol Histpathol. 37:65–68. 2015.PubMed/NCBI
|
|
34
|
Pomerantz M: Active Surveillance:
Pathologic and Clinical Variables Associated with Outcome. Surg
Pathol Clin. 8:581–585. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bellardita L, Valdagni R, van den Bergh R,
Randsdorp H, Repetto C, Venderbos LD, Lane JA and Korfage IJ: How
does active surveillance for prostate cancer affect quality of
life? A systematic review. Eur Urol. 67:637–645. 2015. View Article : Google Scholar
|
|
36
|
Kwon O and Hong S: Active surveillance and
surgery in localized prostate cancer. Minerva Urol Nefrol.
66:175–187. 2014.PubMed/NCBI
|
|
37
|
Lou DY and Fong L: Neoadjuvant therapy for
localized prostate cancer: Examining mechanism of action and
efficacy within the tumor. Urol Oncol. 34:182–192. 2016. View Article : Google Scholar
|
|
38
|
Marshall S and Taneja S: Focal therapy for
prostate cancer: The current status. Prostate Int. 3:35–41. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Andreoiu M and Cheng L: Multifocal
prostate cancer: Biologic, prognostic, and therapeutic
implications. Hum Pathol. 41:781–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Duan Y, Tan Z, Yang M, Li J, Liu C, Wang
C, Zhang F, Jin Y, Wang Y and Zhu L: PC-3-Derived Exosomes Inhibit
Osteoclast Differentiation by Downregulating miR-214 and Blocking
NF-κB Signaling Pathway. BioMed Res Int. 2019:86508462019.
View Article : Google Scholar
|
|
41
|
Li SL, An N, Liu B, Wang SY, Wang JJ and
Ye Y: Exosomes from LNCaP cells promote osteoblast activity through
miR-375 transfer. Oncol Lett. 17:4463–4473. 2019.PubMed/NCBI
|
|
42
|
Krishn SR, Singh A, Bowler N, Duffy AN,
Friedman A, Fedele C, Kurtoglu S, Tripathi SK, Wang K, Hawkins A,
et al: Prostate cancer sheds the αvβ3 integrin in vivo through
exosomes. Matrix Biol. 77:41–57. 2019. View Article : Google Scholar
|
|
43
|
McAtee CO, Booth C, Elowsky C, Zhao L,
Payne J, Fangman T, Caplan S, Henry MD and Simpson MA: Prostate
tumor cell exosomes containing hyaluronidase Hyal1 stimulate
prostate stromal cell motility by engagement of FAK-mediated
integrin signaling. Matrix Biol. 78-79:165–179. 2019. View Article : Google Scholar
|
|
44
|
Panigrahi GK, Praharaj PP, Peak TC, Long
J, Singh R, Rhim JS, Abd Elmageed ZY and Deep G: Hypoxia-induced
exosome secretion promotes survival of African-American and
Caucasian prostate cancer cells. Sci Rep. 8:38532018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ramteke A, Ting H, Agarwal C, Mateen S,
Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R and Deep
G: Exosomes secreted under hypoxia enhance invasiveness and
stemness of prostate cancer cells by targeting adherens junction
molecules. Mol Carcinog. 54:554–565. 2015. View Article : Google Scholar
|
|
46
|
Soekmadji C, Riches JD, Russell PJ,
Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM, Hill MM
and Nelson CC; Australian Prostate Cancer Collaboration
BioResource: Modulation of paracrine signaling by CD9 positive
small extracellular vesicles mediates cellular growth of androgen
deprived prostate cancer. Oncotarget. 8:52237–52255. 2016.
|
|
47
|
Gitenay D and Baron VT: Is EGR1 a
potential target for prostate cancer therapy? Future Oncol.
5:993–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pagel JI and Deindl E: Early growth
response 1 - a transcription factor in the crossfire of signal
transduction cascades. Indian J Biochem Biophys. 48:226–235.
2011.PubMed/NCBI
|
|
49
|
Adamson E, de Belle I, Mittal S, Wang Y,
Hayakawa J, Korkmaz K, O'Hagan D, McClelland M and Mercola D: Egr1
signaling in prostate cancer. Cancer Biol Ther. 2:617–622. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Adamson ED and Mercola D: Egr1
transcription factor: Multiple roles in prostate tumor cell growth
and survival. Tumour Biol. 23:93–102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Baron A, Migita T, Tang D and Loda M:
Fatty acid synthase: A metabolic oncogene in prostate cancer? J
Cell Biochem. 91:47–53. 2004. View Article : Google Scholar
|
|
52
|
Zadra G, Photopoulos C and Loda M: The fat
side of prostate cancer. Biochim Biophys Acta. 1831:1518–1532.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Duijvesz D, Versluis CY, van der Fels CA,
Vredenbregt-van den Berg MS, Leivo J, Peltola MT, Bangma CH,
Pettersson KS and Jenster G: Immuno-based detection of
extracellular vesicles in urine as diagnostic marker for prostate
cancer. Int J Cancer. 137:2869–2878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pan J, Alimujiang M, Chen Q, Shi H and Luo
X: Exosomes derived from miR-146a-modified adipose-derived stem
cells attenuate acute myocardial infarction-induced myocardial
damage via downregulation of early growth response factor 1. J Cell
Biochem. 120:4433–4443. 2019. View Article : Google Scholar
|
